Not a twitter feed I would trust in any way shape or form.

Are you perturbed that Cytodyn will beat out ATHX's Multistem?

That was in an ARDS only study. Add in COVID-19's hematological problems and immune suppression and then where will it be?

Nothing going for it?
Science not hope

Viruses don't automatically stop being active at a preset time. They persist until the host body or drug intervention kills them off or the host dies. If there's an active viral load the chance of transmission still exists. So I call bollocks on that study.

remdesivir - An antiviral that does nothing except for in a small subset of the population (the middle of severity modalities) shows either a flawed study or a flawed analysis.

That the NEJM says that one should also take into account the Chinese study which showed viral load reduction no better than placebo is very telling.

Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31180-6/fulltext

They already had supply chains in Brazil and Mexico prior to the scam reverse merger with RBNW. Why would they feel the need to lie? Because it makes it seem like the scam is not a scam.

What are the names of those analysts?

I think you must be under a misapprehension. Leronlimab is a drug not a test. What the price will be for COVID-19 is unknown. If we sell at a discount of $1000 a dose then that 1 million doses becomes $1 billion. Another 3 million doses equals $4 billion.

But thanks for bringing it up so the profit potential could be explained properly.

But here's the catch in GILD needing leronlimab, the trial will show leronlimab superior to remdesivir and remdesivir adding no benefit. After that no one will need or want remdesivir.

They aren't controlling the trial.

Too bad someone loaded Gilead's gun with blank cartridges.

They would not name Cytodyn because of leronlimab. It would be mentioned on mainstream news because of remdesivir.

I see Delaware's corporate anti-hostile takeover protections putting a stop to any of that nonsense.

Hepatitis is in the disease list so eventually we'll start a trial.

They'll ask for all safety data from both HIV trials, then complain they don't like our mock datasets.

Well that's one way to bring down the market cap.

By near term you must mean tomorrow, certainly you don't mean within a month or two.

An R/S alone would not put it on Nasdaq or NYSE, so much for the institutional investors.

Registering shares itself makes the company no money. However some of those shares were warrants and options that were converted. The conversion brings in some money.

The plus side of Gilead stopping their trials is that there will be more patients available to enroll into our trials.

EIDD-2801 is like remdesivir an antiviral nucleoside analog. The very first effective one was AZT used against HIV. What do we now about ANAs? From HIV we know it can accelerate mutational differentiation in the virus that can lead to the drug being used becoming ineffective.

In the short term an ANA might be an effective strategy, in the long term probably not.

Leronlimab - Disease List (updated)
An incomplete list of potential treatment targets for leronlimab.
Allergies (anaphylactic shock)
Alzheimer's
Asthma
Atherosclerosis
Atopic Dermatitis
Cancer
Coeliac Disease
Chronic Fatigue Syndrome
Chronic Kidney Disease (underlying pathologies)
COPD
COVID-19 (and other coronaviruses)
Crohn's Disease
Colitis
Dermatomyositis
Diabetes (type 1 and 2)
Duchenne Muscular Dystrophy (possibly other muscular dystrophies also)
Emphysema
Fibromyalgia
Grave’s Disease
Guillain-Barre Syndrome
GVHD
Hashimoto’s Thyroiditis
Hepatitis (autoimmune)
HIV
Idiopathic Pulmonary Fibrosis
Inflammatory Bowel Disease
Influenza (severe)
Kawasaki Syndrome
Lambert-Eaton Syndrome
Lupus
Marshall’s syndrome (PFAPA)
Multiple Sclerosis
Myasthenia Gravis
Myocarditis
NASH
Neurofibromatosis
Parkinson's Disease
Pemphigus
Pneumonia
Polymyositis
Post-Myocardial Infarction Syndrome
Psoriasis
Rheumatic Fever
Rheumatoid Arthritis
Sarcoidosis
Scleroderma
Sickle Cell Disease (anti-inflammatory effect)
Sjogren’s Syndrome
Stroke
Tuberculosis
Vasculitis

Not unless everyone else converts their warrants.

It details the conversion of warrants and options to shares of stock.

See, I was right.

The EU has approved many drugs before FDA approval. We just need clinical trials there too.

Remdesivir EUA seemed to be a week or two at most.

They have until July 31st to file.

In the case of Cytodyn - buy the rumor, don't sell until at least 20 indications are approved by the FDA.

If the Mexico study happens we might even be able to get some mainstream press.

The correction from the PR was first posted on the messageboards. It does make you wonder.

Don't trust your family or friends either, everyone is conspiring against you.

How does an antiviral that doesn't kill the virus do anything? By tweaking the study of course.

At every price point the shorts claim it will go down too.

STAT NEWS OFFICIALLY HAS A CREDIBILITY PROBLEM
https://www.classaction.com/news/stat-news-credibility-problem/

Leronlimab on it's own should be very beneficial. Sarah would not qualify for the trial but could get an EIND for first injection here and the UK has a compassionate use exemption.

Is that anything like AF, Culper, and a myriad of other "sources" coordinating short attacks?

What would they make on the stock after COVID-19 and HIV approval? They're giving themselves the shaft by selling now.

https://www.springernature.com/gp/authors/campaigns/in-review

I would think a 60% reduction in viral load would be very beneficial to patients whose organ damage hasn't become so severe that death is inevitable. Hopefully the doctors at Montefiore have learned to give leronlimab to patients first rather than as a last resort.

He is often right. But in small biopharmacy stocks, going negative is like shooting fish in a barrel. Most drugs and biopharmaceutical companies fail and of those that don't finances, small patients populations or other problems bedevil most of the others. He spouts off having done little to no due diligence which is why when he's wrong, he's spectacularly wrong.

Also having mentored under Jim Cramer who has gone negative on stocks he's shorted and looking like he's using Jim's playbook, I wouldn't trust a single opinion of his.

Cytodyn is one of his spectacular failures. Financing might be seat of the pants but can be overcome. Leronlimab itself is a grand slam with more revenue potential than any drug current;y in existence.

With CTSO, Cytodyn will claim part of it's market but do less damage then it will to big pharmaceutical companies.

ps. Adam Feuerstein is also a general all around douchebag.

First rule of thumb in investing - If a stock goes down always sell, if you're lucky you can buy it back at a higher price.